Jefferies is raising its price target on Insulet Corp. PODD from $20 to $24 after the company submitted an application to the FDA.
In the report, Jefferies explains, “Insulet released 1Q results of $28.3mn on par with expectations reflecting seasonal softness as insurance deductibles reset; full year guidance was kept at $123-133mn. Most importantly, the company submitted their 510(k) application to the FDA for the next generation pod and remains well positioned for an approval by year end.”
Jefferies maintains a Buy rating on the stock.
PODD closed yesterday at $20.58.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorPrice TargetAnalyst RatingsHealth CareHealth Care EquipmentInsulet Corp.Jefferies & Co.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in